Table 5.

Doubly robust estimators of the effect of ALBI score on ORR, DCR, PFS, and OS in the 79 patients with hepatocholangiocarcinoma treated either by TKI or by platinum-based regimen

Outcomes	Adjusted† HR/OR*(95% CI)	95% CI of adjusted† HR/OR*	Adjusted† p value
ALBI versus ORR	0.427	0.043–4.285	0.433
ALBI versus DCR	0.339	0.057–2.001	0.196
ALBI versus PFS	1.121	0.625–2.011	0.685
ALBI versus OS	2.517	1.412–4.487	0.003

^*Right-censored outcome (i.e., OS and PFS) regressions were Cox regressions (HR with 95% CI) and binary outcome (i.e., ORR and DCR) regressions were logistic regressions (OR with 95% CI).

^†Adjustment was done regarding the first-line regiment (TKI vs. platinumbased regimens), serum level of AFP and CA19-9, unique versus multiple tumors, the maximal diameter of tumor(s), the sum of diameters of tumor(s), the presence of metastasis, macrovascular invasion, and previous local or locoregional treatments. The analysis was performed using doubly robust estimators (combinations of the appropriate outcome regression [Cox or logistic regression] with a model of exposure using an inverse probability weighting based on covariate balancing propensity scores).